Healthcare’s Recovery Gets More Selective

Good morning, ! Healthcare’s recovery is getting more selective. Payers are stabilizing, capital is moving into targeted deals, and investors are looking beyond growth toward margins, execution, and strategic positioning.

This week, we look at where healthcare capital is moving—and what the next pressure points could be.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

Join PE150 and Caplink for our AI & Data Insight Breakfast in London. Register here.

MICROSURVEY

Margins Edge Out Volume as H2’s Hospital KPI

Hospital investors are watching profitability more closely than growth heading into H2 2026. In our latest HC150 survey of 133 respondents, 29% selected operating margin as the hospital KPI they will monitor most closely, ahead of bad debt at 26%. Admissions and outpatient volumes each drew 23%.

The narrow spread matters. Operating margin leads, but only slightly, suggesting investors are not underwriting hospital performance through a single metric. Instead, attention is split between whether hospitals can protect earnings, contain revenue leakage, and sustain patient activity.

Bad debt’s 26% showing is particularly notable. Its proximity to operating margin suggests investors are looking beyond headline demand and toward the quality of revenue conversion.

Why it matters: H2 scrutiny will center on whether hospitals can translate patient volumes into durable profitability. Volume growth alone may carry less weight if collections weaken or margins fail to follow.

Bottom line: For hospitals, growth still matters. Converting that growth into cash and margin matters more. (More)

PRESENTED BY CAPLINK X PE 150

You’re invited: Where AI Meets Private Equity

Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.

On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.

The morning will feature three practitioner-led discussions:

• AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies. Sponsored by Exact Insight.

• AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management. Sponsored by our M&A Technology Partner Datasite.

• Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.

Interested in attending? Register or request the full agenda here.

Interested in sponsoring? Email [email protected] 

HEADLINE OF THE WEEK

Payers Find Their Footing, but Medicaid Is the Next Stress Test

After a punishing 2025, managed care is showing signs of stabilization. UnitedHealth posted $5.5B in Q2 profit, up from $3.4B a year earlier, while CVS nearly tripled quarterly profit to roughly $3B. Centene swung from a $458M loss to a $1.2B profit.

The recovery suggests Medicare Advantage repricing, geographic exits, and tighter cost management are beginning to work. But the pressure has not disappeared. It is shifting.

Medicaid is emerging as the next fault line. Centene’s Medicaid medical loss ratio reached 93.9%, while insurers are warning of negative margins as enrollment declines and states prepare for work requirements beginning January 2027. Humana’s decision to maintain guidance despite improving MA indicators adds another note of caution.

Why it matters: For investors, Q2 strengthens the case that the worst of the MA reset may be passing, but it does not signal a broad payer recovery. Earnings dispersion will increasingly depend on business mix and execution.

Bottom line: Managed care is moving from an industry-wide cost shock to a company-specific execution story. The next test is Medicaid. (More)

DEAL OF THE WEEK

Jazz Pharmaceuticals Bets $1.3B on a Rare Epilepsy Breakthrough

Jazz Pharmaceuticals is making a major move into genetic epilepsy, agreeing to acquire Actio Biosciences for $820 million upfront and up to $500 million in milestones. The deal gives Jazz access to ABS-1230, an investigational treatment for KCNT1-related epilepsy, a rare genetic disorder with no FDA-approved therapies.

The transaction expands Jazz’s neuroscience portfolio beyond its established Epidiolex franchise while giving Actio the resources to advance ABS-1230 through development. The deal is particularly notable for its upfront consideration: Jazz is putting $820 million of capital at risk before milestones, signaling confidence in the program’s potential.

For Jazz, the transaction reflects a broader strategy of using M&A to build positions in high-value rare diseases where limited treatment options can support significant commercial opportunities. For Actio, the acquisition provides a path to scale a highly specialized program within an established global pharmaceutical platform.

The bigger takeaway: rare-disease assets with differentiated biology and significant unmet need continue to command substantial strategic premiums—even before regulatory approval.

Read more

DEALS TRACKER

$1.1B | Varex Imaging → Teledyne Technologies
Teledyne agreed to acquire Varex Imaging for $18.90 per share in cash, adding a leading X-ray tube and detector maker to its imaging portfolio in a major healthcare technology consolidation. Read more

Up to $800M | Alkeus Pharmaceuticals → Tarsus Pharmaceuticals
Tarsus agreed to acquire Alkeus for $450M upfront plus up to $350M in milestones, adding Phase 3 gildeuretinol to its ophthalmology portfolio and expanding its position in eye care. Read more

$287.5M | VitalConnect → iRhythm Holdings
iRhythm agreed to acquire VitalConnect for $237.5M in cash and approximately $50M in stock, expanding its cardiac monitoring platform from ambulatory care into inpatient and hospital-to-home settings. Read more

$77M | InduPro — Series B Financing
InduPro raised $77M in Series B financing as it advanced its lead oncology program, IDP-001, into Phase 1, bringing together biotech investors and strategic pharmaceutical participants. Read more

REGIONAL FOCUS

The US-China Biomanufacturing Race Is Moving Beyond Pharma

Biomanufacturing is becoming less a biotech niche and more a strategic industrial capability. A new analysis from the Carnegie Endowment compares the U.S. and its key partners—Germany, the UK, Japan and South Korea—with China across the biomanufacturing technology stack.

The table above highlights the competitive picture across the R&D layer: biobanks and genetic data, research consumables and equipment, and DNA sequencing and synthesis. The takeaway is nuanced. The U.S. and its partners retain an advantage in most high-value research infrastructure, while China is steadily closing the gap through domestic investment, scale and state support.

For healthcare investors, the important shift is what comes next. Biomanufacturing is expanding beyond pharmaceuticals into agriculture, critical minerals, fertilizers, materials and industrial chemicals. China’s strength in scale-intensive manufacturing could therefore become more strategically important as the addressable market broadens.

Bottom line: the next biomanufacturing race may be won less by whoever discovers the best molecule—and more by whoever controls the infrastructure needed to manufacture the next generation of products.

Read more

INTERESTING ARTICLES